Selective Serotonin Reuptake Inhibitors and Associated Bleeding Risks: A Narrative and Clinical Review

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Medicine

Background:

• Major Depressive Disorder (MDD) is a leading cause of global disability.
• The monoamine deficiency hypothesis links depression to reduced neurotransmitters like serotonin.
• Selective Serotonin Reuptake Inhibitors (SSRIs) are a primary treatment for MDD, increasing synaptic serotonin.

Purpose of the Study:

• To review the current literature on the association between SSRI use and bleeding risk.
• To explore the mechanisms by which SSRIs may influence bleeding.
• To highlight the need for further investigation into SSRI-related bleeding complications.

Main Methods:

• Literature review of studies investigating SSRI effects on bleeding.
• Analysis of proposed mechanisms involving platelet function and gastric acid secretion.
• Examination of bleeding risks associated with SSRI combinations (NSAIDs, vitamin K antagonists).

Main Results:

• Evidence is conflicting regarding SSRI-associated bleeding and perioperative risk.
• SSRIs can affect platelet aggregation and serotonin storage in platelets.
• Increased gastric acid secretion and upper GI ulceration risk are potential SSRI side effects.
• Combinations of SSRIs with NSAIDs or vitamin K antagonists may significantly elevate bleeding risk.

Conclusions:

• The bleeding risk associated with SSRIs requires further comprehensive study.
• Understanding these risks is crucial given the high prevalence of SSRI use.
• Clinical guidelines may need to address the perioperative and combined medication bleeding risks of SSRIs.